Energenesis Biomedical, founded in 2012, is a biotech company publicly listed on the Taiwan Stock Exchange Corporation (TWSE: 6657) in 2023. With over a decade of commitment, our team has pioneered the ENERGI-Platform, a novel approach using small molecule drugs to boost cellular energy levels. This technology activates self-healing mechanisms within cells, empowering us to explore innovative ways of addressing challenging diseases. Pipeline: ENERGI-F703DFU: gel for Diabetic foot ulcers (Phase III, recruiting in the US and Taiwan) ENERGI-F701: hair tonic for Alopecia (Phase II, completed) ENERGI-F703EB: cream for Epidermolysis Bullosa (in preparation for Phase II, granted ODD&RPD) ENERGI-F705PD : oral medicine for Parkinson’s disease (in preparation for Phase II)
| Website | https://www.energenesis-biomedical.com/en |
| Revenue | $7 million |
| Employees | 19 (13 on RocketReach) |
| Founded | 2012 |
| Phone | +61 2 2627 0835 |
| Technologies |
JavaScript
,
PHP
,
Font Awesome
+1 more
(view full list)
|
| Industry | Biotechnology, Government |
| Keywords | Biotech Platform, Biotechnology Investment, Biotechnology, Therapeutics, Pharmaceutical, Biomedical Engineering, Biopharma, Pharmaceutical Research, Innovative Therapies, Biomedical, Drug Development, Precision Medicine, Life Sciences, Small Molecule Drugs, Healthcare, Regenerative Medicine, Health Technology, Molecular Medicine, Medical Technology, Clinical Trials |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular Energenesis Biomedical employee's phone or email?
The Energenesis Biomedical annual revenue was $7 million in 2026.
Eric Wu is the Director of Business Development of Energenesis Biomedical.
13 people are employed at Energenesis Biomedical.
The NAICS codes for Energenesis Biomedical are [54, 541].
The SIC codes for Energenesis Biomedical are [87, 873].